11 stories found
Extended and midday trading sessions saw significant price swings across multiple sectors, with notable movements reported for Snowflake, Tesla, Meta, and biotech firms following corporate developments and macroeconomic shifts.
Wells Fargo analysts raised their price target for Ultragenyx Pharmaceutical following positive Phase 3 trial results, citing improved therapeutic outcomes and commercial potential.
Multiple companies have released their recent financial performance, detailing GAAP or Non-GAAP earnings per share and revenue figures. These reports indicate whether the companies met, beat, or missed analyst expectations for their latest reporting period.
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP The Globe and Mail
Ultragenyx Pharmaceutical saw its stock drop sharply after announcing that a pivotal Phase 3 trial for its experimental Angelman syndrome therapy did not meet primary endpoints. Several financial analysts downgraded the company, though some investors remain optimistic about its broader pipeline.
This report identifies Intuit (INTU), Hamilton Lane (HLNE), and Ultragenyx Pharmaceutical (RARE) as some of the best buy-the-dip stocks. It provides reasons why these companies are considered strong investment opportunities after a market downturn.
Ultragenyx Pharmaceutical is garnering bullish sentiment from investors in anticipation of its forthcoming GTX-102 Phase 3 trial for Angelman Syndrome, signaling confidence in its clinical development.
An analysis presents a 'Bull Case Theory' for Ultragenyx Pharmaceutical Inc. (RARE), outlining potential positive financial prospects for the company.
Shares of biotech firm Ultragenyx plummeted by nearly half in intraday trading following a significant corporate disclosure that triggered severe investor sell-offs.
Optimism for Ultragenyx Pharmaceutical (RARE) is being fueled by institutional confidence in its drug candidate, GTX-102.
Ultragenyx Pharmaceutical Inc. has been downgraded to a 'neutral' rating by Goldman Sachs, following the release of new data concerning its drug setrusumab.